US7053070B2
(en)
*
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
US7235551B2
(en)
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
CZ20031125A3
(en)
|
2000-10-23 |
2003-10-15 |
Smithkline Beecham Corporation |
Novel compounds
|
NZ526961A
(en)
*
|
2001-02-12 |
2005-03-24 |
F |
6-substituted pyrido-pyrimidines
|
EP1364950A4
(en)
*
|
2001-02-26 |
2005-03-09 |
Tanabe Seiyaku Co |
Pyridopyrimidine or naphthyridine derivative
|
US20030100572A1
(en)
*
|
2001-06-21 |
2003-05-29 |
Ariad Pharmaceuticals,Inc. |
Novel pyridopyrimidones and uses thereof
|
US20030105115A1
(en)
*
|
2001-06-21 |
2003-06-05 |
Metcalf Chester A. |
Novel pyridopyrimidines and uses thereof
|
EA007395B3
(en)
*
|
2002-01-22 |
2018-02-28 |
Уорнер-Ламберт Компани Ллс |
2-(PYRIDINE-2-YLAMINO)PYRIDO[2,3-d]PYRIMIDIN-7-ONES
|
PL373339A1
(en)
|
2002-04-19 |
2005-08-22 |
Smithkline Beecham Corporation |
Novel compounds
|
CA2494061C
(en)
|
2002-07-31 |
2011-06-14 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
ATE380810T1
(en)
|
2002-10-09 |
2007-12-15 |
Critical Outcome Technologies |
PROTEIN TYROSINE KINASE INHIBITORS
|
WO2004065378A1
(en)
*
|
2003-01-17 |
2004-08-05 |
Warner-Lambert Company Llc |
2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
|
US6861422B2
(en)
|
2003-02-26 |
2005-03-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
AU2004268621C1
(en)
|
2003-08-29 |
2011-08-18 |
Exelixis, Inc. |
c-Kit modulators and methods of use
|
WO2005047284A1
(en)
|
2003-11-13 |
2005-05-26 |
F. Hoffmann-La Roche Ag |
Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
|
DE102004029784A1
(en)
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
|
DE102004033670A1
(en)
|
2004-07-09 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New pyridodihydropyrazinone, process for its preparation and its use as a medicament
|
FR2873118B1
(en)
|
2004-07-15 |
2007-11-23 |
Sanofi Synthelabo |
PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
|
US20060074088A1
(en)
|
2004-08-14 |
2006-04-06 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones for the treatment of cancer diseases
|
US7728134B2
(en)
|
2004-08-14 |
2010-06-01 |
Boehringer Ingelheim International Gmbh |
Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
|
US7759485B2
(en)
|
2004-08-14 |
2010-07-20 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of dihydropteridinones
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
US20060035903A1
(en)
|
2004-08-14 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Storage stable perfusion solution for dihydropteridinones
|
EP1630163A1
(en)
|
2004-08-25 |
2006-03-01 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinones, methods for their preparation and their use as drugs
|
CA2575804A1
(en)
*
|
2004-08-26 |
2006-03-02 |
Boehringer Ingelheim International Gmbh |
Pteridinones used as plk (polo like kinase) inhibitors
|
DE102004058337A1
(en)
|
2004-12-02 |
2006-06-14 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Process for the preparation of fused piperazin-2-one derivatives
|
AU2006204724A1
(en)
|
2005-01-14 |
2006-07-20 |
Millennium Pharmaceuticals, Inc. |
Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
|
EP1868612A4
(en)
|
2005-03-25 |
2010-03-24 |
Glaxo Group Ltd |
Novel compounds
|
UY29440A1
(en)
|
2005-03-25 |
2006-10-02 |
Glaxo Group Ltd |
NEW COMPOUNDS
|
MX2007012951A
(en)
|
2005-03-25 |
2008-01-11 |
Glaxo Group Ltd |
Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives.
|
PE20061193A1
(en)
|
2005-03-25 |
2006-12-02 |
Glaxo Group Ltd |
DERIVATIVES OF 3,4-DIHYDROPYRIMIDO [4,5-d] PYRIMIDIN-2- [1H] -0NA AS KINASE INHIBITORS p38
|
US7737155B2
(en)
*
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
FR2887882B1
(en)
*
|
2005-07-01 |
2007-09-07 |
Sanofi Aventis Sa |
PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
|
TW200800983A
(en)
|
2005-09-14 |
2008-01-01 |
Janssen Pharmaceutica Nv |
5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
|
US7642270B2
(en)
|
2005-09-14 |
2010-01-05 |
Janssen Pharmaceutica N.V. |
5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
|
EA016945B1
(en)
*
|
2005-10-07 |
2012-08-30 |
Экселиксис, Инк. |
PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
|
CA2624965A1
(en)
*
|
2005-10-07 |
2007-04-19 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of pi3k.alpha.
|
FR2896246B1
(en)
|
2006-01-13 |
2008-08-15 |
Sanofi Aventis Sa |
PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
|
US7439358B2
(en)
|
2006-02-08 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
|
ES2366489T3
(en)
|
2006-09-15 |
2011-10-20 |
Pfizer Products Inc. |
PIRID COMPOUND (2,3-D) PIRIDINONE AND ITS USE AS PI3 INHIBITORS.
|
BRPI0715566A2
(en)
*
|
2006-10-16 |
2013-07-02 |
Gpc Biotech Inc |
compound, prodrug, pharmaceutical composition, use of a compound, method for inhibiting cell proliferation and method for synthesizing a compound
|
EP1914234A1
(en)
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
US20080114007A1
(en)
*
|
2006-10-31 |
2008-05-15 |
Player Mark R |
5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
|
FR2910813B1
(en)
|
2006-12-28 |
2009-02-06 |
Sanofi Aventis Sa |
NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
|
BRPI0809998B8
(en)
*
|
2007-04-03 |
2021-05-25 |
Array Biopharma Inc |
imidazo[1,2-a]pyridine compound as receptor tyrosine kinase inhibitors, their uses, their preparation processes and pharmaceutical compositions
|
JP5129812B2
(en)
|
2007-06-15 |
2013-01-30 |
Msd株式会社 |
Bicycloaniline derivatives
|
WO2009019205A1
(en)
|
2007-08-03 |
2009-02-12 |
Boehringer Ingelheim International Gmbh |
Crystalline form of a dihydropteridione derivative
|
CN101945867A
(en)
|
2007-12-19 |
2011-01-12 |
安姆根有限公司 |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
WO2009079797A1
(en)
|
2007-12-26 |
2009-07-02 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
EP2100894A1
(en)
*
|
2008-03-12 |
2009-09-16 |
4Sc Ag |
Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
|
EP2278973B1
(en)
|
2008-04-07 |
2011-11-02 |
Amgen Inc. |
Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
EP3023426A1
(en)
|
2008-07-17 |
2016-05-25 |
Critical Outcome Technologies, Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
UY32153A
(en)
|
2008-09-30 |
2011-04-29 |
Exelixis Inc |
PY13KA (ALFA) AND MTOR PYRIDOMIDINONE INHIBITORS
|
TW201100441A
(en)
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
JP2013507395A
(en)
*
|
2009-10-09 |
2013-03-04 |
アフラクシス・インコーポレイテッド |
8-Ethyl-6- (aryl) pyrido [2,3-D] pyrimidin-7 (8H) -one for the treatment of CNS disorders
|
CA2784749C
(en)
|
2009-12-18 |
2017-12-12 |
E. Premkumar Reddy |
Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
|
US8901137B2
(en)
|
2010-02-09 |
2014-12-02 |
Exelixis, Inc. |
Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
|
CA2794952C
(en)
|
2010-04-01 |
2018-05-15 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
NZ606281A
(en)
|
2010-08-05 |
2014-09-26 |
Univ Temple |
2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof
|
US8546566B2
(en)
|
2010-10-12 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Process for manufacturing dihydropteridinones and intermediates thereof
|
WO2012074951A1
(en)
|
2010-11-29 |
2012-06-07 |
OSI Pharmaceuticals, LLC |
Macrocyclic kinase inhibitors
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
ES2543569T3
(en)
|
2011-03-23 |
2015-08-20 |
Amgen Inc. |
Dual condensed tricyclic inhibitors of CDK 4/6 and FLT3
|
CA2836410C
(en)
*
|
2011-05-17 |
2019-08-20 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
US9370535B2
(en)
|
2011-05-17 |
2016-06-21 |
Boehringer Ingelheim International Gmbh |
Method for treatment of advanced solid tumors
|
MX2014010176A
(en)
|
2012-02-23 |
2014-11-10 |
Abbvie Inc |
Pyridopyrimidinone inhibitors of kinases.
|
PT2958916T
(en)
*
|
2013-02-21 |
2018-11-21 |
Pfizer |
Solid forms of a selective cdk4/6 inhibitor
|
JP2016525532A
(en)
|
2013-07-26 |
2016-08-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Treatment of myelodysplastic syndrome
|
WO2016015597A1
(en)
*
|
2014-07-26 |
2016-02-04 |
Sunshine Lake Pharma Co., Ltd. |
Compounds as cdk small-molecule inhibitors and uses thereof
|
US9867831B2
(en)
|
2014-10-01 |
2018-01-16 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
|
US10449195B2
(en)
|
2016-03-29 |
2019-10-22 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical formulation of palbociclib and a preparation method thereof
|
TWI646094B
(en)
*
|
2016-06-01 |
2019-01-01 |
大陸商貝達藥業股份有限公司 |
Crystal form of inhibitory protein kinase active compound and application thereof
|
LT3497103T
(en)
|
2016-08-15 |
2021-07-26 |
Pfizer Inc. |
Pyridopyrimdinone cdk2/4/6 inhibitors
|
CN110809576B
(en)
*
|
2017-03-03 |
2022-08-30 |
奥克兰联合服务有限公司 |
FGFR kinase inhibitor and pharmaceutical use
|
KR20200131246A
(en)
|
2018-02-15 |
2020-11-23 |
누베이션 바이오 인크. |
Heterocyclic compounds as kinase inhibitors
|
CN113166148B
(en)
*
|
2018-12-07 |
2024-04-12 |
杭州英创医药科技有限公司 |
Heterocyclic compounds as CDK-HDAC dual pathway inhibitors
|
CN112759589B
(en)
*
|
2019-11-01 |
2022-04-08 |
暨南大学 |
Pyrimidopyridinones and their use
|
US11697648B2
(en)
|
2019-11-26 |
2023-07-11 |
Theravance Biopharma R&D Ip, Llc |
Fused pyrimidine pyridinone compounds as JAK inhibitors
|
JP2024508901A
(en)
*
|
2021-03-08 |
2024-02-28 |
曁南大学 |
Pyridopyrimidine compounds and their uses
|
CN117720531A
(en)
*
|
2022-09-16 |
2024-03-19 |
华东师范大学 |
Pyridopyrimidine derivatives as RSK inhibitors and use thereof
|